Literature DB >> 26885029

Hirudin inhibits cell growth via ERK/MAPK signaling in human glioma.

Li Zhao1.   

Abstract

Glioma is one of the most common intracranial tumors, and the prognosis is poor though more and more treatments are employed. ERK/MAPK signaling has been reported to be associated with glioma. In the present study, we aimed to investigate hirudin as an antineoplastic drug inhibits ERK/MAPK signaling in glioma growth in vitro. The cell proliferation and apoptosis rate were detected using MTS and Annexin V staining assay, cell cycle distribution was detected using flowcytometry assay. Furthermore, the relevant molecules of ERK/MAPK signaling were examined using Western blot analysis and immunofluorescence staining assay. We provide the first evidence that hirudin increase inactivation state of ERK1/2, down-regulate the expression of canonical ERK/MAPK signaling pathway and establish an important role for hirudin in the treatment of glioma cells.

Entities:  

Keywords:  ERK/MAPK signaling; Hirudin; cell growth; glioma

Year:  2015        PMID: 26885029      PMCID: PMC4723874     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  15 in total

Review 1.  Hirudin--the long and stony way from an anticoagulant peptide in the saliva of medicinal leech to a recombinant drug and beyond. A historical piece.

Authors:  Götz Nowak; Karsten Schrör
Journal:  Thromb Haemost       Date:  2007-07       Impact factor: 5.249

2.  A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients.

Authors:  An-An Yin; Sang Cai; Yu Dong; Lu-Hua Zhang; Bo-Lin Liu; Jin-Xiang Cheng; Xiang Zhang
Journal:  J Neurooncol       Date:  2013-11-01       Impact factor: 4.130

3.  Effect of hirudin on the levels of acute lung injury rat tumor necrosis factor-α and matrix metalloproteinase-12.

Authors:  Yongxia Bao; Ying Geng; Hui Jing
Journal:  Mol Med Rep       Date:  2011-12-27       Impact factor: 2.952

4.  Recombinant hirudin suppresses the viability, adhesion, migration and invasion of Hep-2 human laryngeal cancer cells.

Authors:  Qian Lu; Mei Lv; Erdong Xu; Fangyu Shao; Ya Feng; Jingru Yang; Lin Shi
Journal:  Oncol Rep       Date:  2015-01-14       Impact factor: 3.906

Review 5.  Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.

Authors:  Kwong-Kwok Wong
Journal:  Recent Pat Anticancer Drug Discov       Date:  2009-01       Impact factor: 4.169

Review 6.  The role of Gliadel wafers in the treatment of high-grade gliomas.

Authors:  Amade Bregy; Ashish H Shah; Maria V Diaz; Hayley E Pierce; Philip L Ames; Daniel Diaz; Ricardo J Komotar
Journal:  Expert Rev Anticancer Ther       Date:  2013-12       Impact factor: 4.512

Review 7.  Understanding high grade glioma: molecular mechanism, therapy and comprehensive management.

Authors:  Yongzhi Wang; Tao Jiang
Journal:  Cancer Lett       Date:  2013-01-20       Impact factor: 8.679

8.  Recombinant hirudin treatment modulates aquaporin-4 and aquaporin-9 expression after intracerebral hemorrhage in vivo.

Authors:  Zhe Sun; Zhenhuan Zhao; Shiguang Zhao; Yi Sheng; Zonghang Zhao; Cheng Gao; Jingwen Li; Xiangzhen Liu
Journal:  Mol Biol Rep       Date:  2008-06-24       Impact factor: 2.316

Review 9.  Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma.

Authors:  Qinglei Gao; Ting Lei; Fei Ye
Journal:  Expert Opin Investig Drugs       Date:  2013-06-04       Impact factor: 6.206

Review 10.  Molecular targeting for malignant gliomas (Review).

Authors:  Yasuko Kondo; Emporia F Hollingsworth; Seiji Kondo
Journal:  Int J Oncol       Date:  2004-05       Impact factor: 5.650

View more
  5 in total

1.  SHP2 regulates proliferation and tumorigenicity of glioma stem cells.

Authors:  Laura Roccograndi; Zev A Binder; Logan Zhang; Nicola Aceto; Zhuo Zhang; Mohamed Bentires-Alj; Ichiro Nakano; Nadia Dahmane; Donald M O'Rourke
Journal:  J Neurooncol       Date:  2017-08-29       Impact factor: 4.130

2.  Knockdown of Angiopoietin-Like Protein 2 Inhibits Proliferation and Invasion in Glioma Cells via Suppressing the ERK/MAPK Signaling Pathway.

Authors:  Li-Kun Yang; Jie Zhu; Yu-Hua Chen; Dong-Liang Wang; Hua Li; Liang-Jun Zhang; Jing-Ru Zhou; Wei Liu
Journal:  Oncol Res       Date:  2017-02-28       Impact factor: 5.574

3.  Hirudin promotes proliferation and osteogenic differentiation of HBMSCs via activation of cyclic guanosine monophosphate (cGMP)/protein kinase-G (PKG) signaling pathway.

Authors:  Shun Cao; Xianghui Li; Ting Feng; Yaqing Li; Hongwei Ding; Lin Xie; Quanhong Yang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

4.  Hirudin Protects Against Kidney Damage in Streptozotocin-Induced Diabetic Nephropathy Rats by Inhibiting Inflammation via P38 MAPK/NF-κB Pathway.

Authors:  Jiarui Han; Xinxin Pang; Yage Zhang; Zining Peng; Xiujie Shi; Yufeng Xing
Journal:  Drug Des Devel Ther       Date:  2020-08-07       Impact factor: 4.162

Review 5.  Pharmacological Activities and Mechanisms of Hirudin and Its Derivatives - A Review.

Authors:  Chen Junren; Xie Xiaofang; Zhang Huiqiong; Li Gangmin; Yin Yanpeng; Cao Xiaoyu; Gao Yuqing; Li Yanan; Zhang Yue; Peng Fu; Peng Cheng
Journal:  Front Pharmacol       Date:  2021-04-16       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.